Antiangiogenic and anticancer molecules in cartilage
Debabrata Patra 1 and Linda J. Sandell 1,2, * Cartilage is one of the very few naturally occurring avascular tissues where lack of angiogenesis is the guiding principle for its structure and function. This has attracted investigators who have sought to understand the biochemical basis for its avascular nature, hypothesising that it could be used in designing therapies for treating cancer and related malignancies in humans through antiangiogenic applications. Cartilage encompasses primarily a specialised extracellular matrix synthesised by chondrocytes that is both complex and unique as a result of the myriad molecules of which it is composed. Of these components, a few such as thrombospondin-1, chondromodulin-1, the type XVIII-derived endostatin, SPARC (secreted protein acidic and rich in cysteine) and the type II collagen-derived N-terminal propeptide (PIIBNP) have demonstrated antiangiogenic or antitumour properties in vitro and in vivo preclinical trials that involve several complicated mechanisms that are not completely understood. Thrombospondin-1, endostatin and the sharkcartilage-derived Neovastat preparation have also been investigated in human clinical trials to treat several different kinds of cancers, where, despite the tremendous success seen in preclinical trials, these molecules are yet to show success as anticancer agents. This review summarises the current state-ofthe-art antiangiogenic characterisation of these molecules, highlights their most promising aspects and evaluates the future of these molecules in antiangiogenic applications.
In designing strategies to counter cancer, restricting or eliminating angiogenic signals from the tumour is the working principle behind several therapeutic applications. An idea that was first seeded by Judah Folkman in the 1970s (Ref. 1) has matured into exponentially expanding treatment opportunities because of an ever-increasing knowledge base in angiogenesis pathways and molecular targets. The discovery of naturally occurring tissues that are antiangiogenic and where antiangiogenesis and lack of vasculature is a guiding principle dictating the developmental outcome has allowed for an increase in identification of antiangiogenic molecules. Chief among these is cartilage, a specialised form of extracellular matrix (ECM) synthesised by chondrocytes.
The characteristic that sets cartilage apart is that it is avascular, and this has piqued the interest of investigators who have sought to understand its avascular nature and to apply its principles to therapeutic applications. It stands to reason that the avascular nature of cartilage would be due to its biochemical composition that antagonises vascular invasion and there has been considerable interest in identifying these antiangiogenic components in cartilage. The primary components of cartilage are the two major macromolecules, type II collagen (Col II) and aggrecan ( Fig. 1) . Minor components include collagens types IX, XI, III, V, VI, X, XII, XIV as well as versican, perlecan, lubricin, biglycan, fibromodulin, thrombospondins (TSPs), chondromodulin-1 (ChM-1), endostatin and secreted protein acidic and rich in cysteine (SPARC), among others (reviewed in Ref. 2) . Although in adults cartilage serves primarily to lubricate the joints, during embryonic development its chief function is to form the template for future skeletal development in mammals.
The process by which cartilage template is replaced by bone is called endochondral ossification, which occurs when the avascular privilege of cartilage is broken down, allowing for vascular invasion and endochondral bone formation. This topic has been well reviewed (Refs 3, 4), but to briefly summarise, the process begins with mesenchymal cell condensations at sites where the future skeletal elements will form; cells in these condensates differentiate to form chondrocytes that secrete a Col-II-rich avascular cartilage, with cells surrounding the chondrocytes forming the perichondrium. To allow for bone formation, the innermost chondrocytes differentiate to form hypertrophic chondrocytes that secrete a type-X-collagen-rich matrix that gets calcified, with the perichondral cells surrounding the hypertrophic chondrocytes differentiating into osteoblasts to form the bone collar. This allows for the vascular endothelial growth factor (VEGF)-dependent vascular invasion of the calcified cartilage matrix from the bone collar, which brings along with it chondroclasts and osteoblasts that degrade and replace the calcified matrix with bone and results in removal of the hypertrophic chondrocytes by apoptosis. This process thus allows for vascular invasion only of the calcified matrix, leaving the rest of cartilage matrix avascular. This is crucial to bone growth because the avascular cartilage continuously provides chondrocytes that differentiate to form hypertrophic chondrocytes that are removed during endochondral bone growth, thus allowing for continuous bone growth. With maturity, the centre of the avascular cartilage undergoes hypertrophic differentiation again to allow vascular invasion and the development of a secondary ossification centre. In adults, most of the cartilage is thus replaced by bone, with the exception of the articular cartilage at the bone ends, which remains avascular to maintain cartilage phenotype and functions to lubricate the joint. Breakdown of the antiangiogenic barrier during diseases such as osteoarthritis and rheumatoid arthritis results in undesirable vascular invasion of the articular cartilage and irreversible cartilage degeneration.
Tumours that exceed 1-2 mm in diameter require new capillary formation or angiogenesis that feeds their growth (Ref. 5) . The recognition of this fundamental principle behind tumour growth has triggered the search for antiangiogenic molecules that would prevent tumour growth. Blessed with its avascular state, cartilage has since then become a prime target for investigation of its antiangiogenic properties (Refs 5, 6) . Although primarily articular cartilage was tested, growth plate chondrocytes also demonstrated antiangiogenic effects (Ref. 7) . These discoveries propelled an interest in the identification of cartilage components that produce these antiangiogenic and antitumour effect with the expectation that these cartilagederived molecules could be used in therapeutic applications to treat tumours and related malignancies. This review summarises the status quo of some antiangiogenic molecules that are present in cartilage.
Neovastat and shark cartilage extract
Neovastat and shark cartilage extract (SCE) are preparations with antiangiogenesis activity derived from shark cartilage. Interest in shark cartilage as a source of anticancer agents grew because of its avascular state coupled with the misconception that sharks do not get cancer. The cartilaginous shark endoskeleton was thus thought to be an ideal source of large quantities of anticancer agents. Current literature finds researchers at extreme ends of the spectrum in The matrix closest to the chondrocytes is indicated as territorial and between the chondrocytes is interterritorial. The cartilage extracellular matrix (ECM) is made of molecules that are synthesised by the chondrocyte. It has two major macromolecules, collagen type II and the large proteoglycan, aggrecan. The aggrecan protein consists of a globular core protein to which are attached chains of chondroitin sulfate (CS) and keratan sulfate (KS). The figure shows aggrecan monomers attached to hyaluronic acid (HA), which is stabilised by the link protein, to form a larger proteoglycan aggregate in interaction with the smaller proteoglycan, fibulin. In addition to these, the cartilage ECM is also composed of minor amounts of other collagens such as collagen types IX, XI, III, V, VI, X, XII, XIV and XVIII (from which endostatin is derived). Collagen type IX has four noncollagenous (NC) domains and has the ability to form heterotypic fibrils with collagen II/XI (shown in the interterritorial matrix) that is coated with smaller proteoglycans such as decorin and fibromodulin. The cartilage intermediate layer protein (CILP) is found primarily in the interterritorial matrix. Other smaller proteoglycans include biglycan, decorin and chondromodulin-1. The other major cartilage proteins are the thrombospondins (TSPs), which consists of TSP1, TSP2 and COMP (cartilage oligomeric matrix protein also known as TSP5). Matrilins 1 and 3 (MAT1, MAT3) are the primary members of the multimeric matrilin family of proteins found in the cartilage. PRELP (proline arginine-rich end leucine-rich repeat protein) and CHAD (chondroadherin) are small leucine-rich repeat proteins (LRRs) that bind to fibre forming collagens with high affinity due to the LRR domain. Syndecan is a heparan sulfate proteoglycan (HSPG) found on the chondrocyte cell surface where it acts as receptors for matrix components such as fibronectin. A number of matricellular proteins such as SPARC (secreted protein acidic and rich in cysteine) are also seen in the cartilage ECM. The cartilage matrix and its composition are reviewed in depth elsewhere (Ref. 2 
Clinical applications with TSP1 and TSP2
The benefits from TSP1 and TSP2 in preclinical 
Endostatin
Endostatin is a 20 kDa fragment derived from the C-terminus of collagen XVIII by the activity of several proteinases, chiefly MMP9 (Refs 110, 111). Endostatin, similar to other inhibitors of angiogenesis, inhibits endothelial cell proliferation and migration and induces apoptosis. It is expressed in cartilage, but is not specific to cartilage and has been detected in both fetal epiphyseal cartilage and adult articular cartilage in humans, rats and mice, where its spatio-temporal distribution might provide an antiangiogenic benefit against cartilage vascularisation (Refs 112, 113). In the meniscal fibrocartilage, its concentration is highest in the completely avascular central portion as compared with the outer region that has some vascular elements.
Antiangiogenic features of endostatin
The mechanism by which endostatin mediates its antiangiogenic effect is complex and is not completely understood because of the myriad pathways that it affects. To highlight some major pathways and recent advances, endostatin can suppress VEGF expression and induce expression of the antiangiogenic pigment epithelium-derived factor (Refs 114, 115, 116) In animal models of ulcerative colitis, increase in VEGF in the colonic tissue was paralleled by a concomitant increase in endostatin as a defense mechanism; the larger the colonic lesion, the greater the increase in VEGF and therefore endostatin (Ref. 133) . Induction of ulcerative colitis in MMP9-deficient mice resulted in less endostatin than in wild-type mice pointing to the in vivo role of MMP9 in generating endostatin from collagen XVIII in lesions. The levels of VEGF and endostatin are often linked, and although the molecular mechanism is not completely understood, VEGF might positively influence endostatin levels through the activation of MMP9 (Ref. 134) . Finally, the large number of genes that are up-or downregulated by endostatin in a genome-wide microarray analysis (Ref. 135) suggests that a lot remains to be understood about endostatin's role in antiangiogenesis. 194 ) that might have a role in keeping the cartilage avascular and could be exploited to kill tumours in vivo. The interaction of recombinant human PIIBNP (GST-PIIBNP) with hCh-1 cells (human chondrosarcoma cell line) was dependent on α V β 5 and α V β 3 integrins and took place in an RGDRGD-dependent manner in vitro. Notably, PIIBNP was able to directly induce cell death in hCh-1 cells, in HeLa cells (cervical carcinoma cell line) and in MDA-MB231 (breast cancer cell line) in a dosedependent manner. Disruption of the RGDintegrin interaction by mutation of the RGDRGD motif in PIIBNP or downregulation of integrin α V in the cell line using siRNA technology significantly reduced cell death. The significance of these in vitro observations hit home when it was realised that PIIBNP exists in cartilage and that normal chondrocytes do not express, or have very low levels of α V , β 5 and β 3 integrins, and presumably therefore are not killed by PIIBNP in vivo. GST-PIIBNP induced necrosis as opposed to apoptotic cell death and was also inhibitory to tumour cell migration. When tested in vivo, GST-PIIBNP suppressed MDA-MB231 induced tumours in nude mice (Fig. 2) demonstrating a 75% reduction in tumour growth over untreated tumours. Several cell types such as endothelial cells, osteoclasts and tumour cells express α V β 5 and α V β 3 integrins, suggesting that PIIBNP might function in vivo to keep the cartilage avascular and free from bone invasion. Indeed, PIIBNP was able to induce apoptotic death in osteoclasts (but not osteoblasts and macrophages) in an RGD-and integrin-dependent manner both in vitro and in vivo (Ref. 195) . These data indicate that PIIBNP might have antiangiogenic role in cartilage and could be used as an anticancer agent.
Derivatives of endostatin with antiangiogenic properties

Future prospects for antiangiogenic research for cartilage-derived molecules
Interest in antiangiogenic molecules has also triggered an interest in their application as anticancer agents in the clinic. The current antiangiogenic modality approved to treat different forms of cancer in the clinic uses monoclonal antibodies against VEGF or to its receptor.
Bevacizumab, an anti-VEGF humanised antibody is used as a treatment for pancreatic cancer, colorectal cancer, nonsmall lung cancer, metastatic renal cancer, carcinoma, glioblastoma and metastatic breast cancer, often in combination with chemotherapy. It is also under investigation for treatment of solid tumours. Despite the tremendous interest generated by the applications of anti-VEGF therapy, it is beleaguered with several drawbacks, primarily its sporadic success in clinical treatments and an inability to provide significant survival benefit (Refs 196, 197) . In fact Avastin, a commercially marketed bevacizumab preparation, was banned recently by the FDA for breast cancer treatment, although it continues to be used for lung and kidney cancers. Furthermore, some tumours demonstrate initial sensitivity to anti-VEGF therapy, but acquire resistance later as a result of the upregulation of bFGF within the tumour after treatment with an anti-VEGFR2 antibody (Ref. 198) . Some tumours also have a natural resistance to anti-VEGF therapy because of CD11b The antitumour activity of the type IIB collagen protein derived PIIBNP propeptide targeting VEGF alone. Indeed, studies on these cartilage-derived antiangiogenic molecules have demonstrated the versatile and complex nature of their antiangiogenic, and in some cases, direct anticancer (ChM-1 and PIIBNP) effect, that is not restricted to targeting VEGF (see Table 1 and Fig. 3) . However, none of these cartilage-derived molecules have so far had much success in clinical trials. Their in vitro assessments and highly successful preclinical trials have had little bearing on their success in humans. Although their in vivo antiangiogenic benefit was largely visible only under certain experimental conditions, such as in a fracture model or cartilage lesion model, deficiency of these molecules in mouse models did not create any abnormal pathology. Perhaps redundancies in functions are responsible for this effect. Discovery of these molecules has not helped to explain how cartilage remains avascular either. Furthermore, Col IIB, ChM-1 and endostatin levels in cartilage drop drastically with maturity and yet the cartilage remains avascular in a healthy individual. Thus, cartilage might derive its antiangiogenic benefit, not from a single molecule, but from the sum total from several individual antiangiogenic molecules, or all cartilage components might need to be present together for it to be antiangiogenic. This suggests that it would be improbable to expect total comprehensive benefit based on administration of a single antiangiogenic molecule in clinical trials. Combinations of molecules, such as TSP1 plus endostatin, in trials might provide better benefit. In preparations of Neovastat, the individual molecules remain largely unidentified. It needs to be ascertained whether Neovastat extract by any chance contains the water-soluble fractions of all the single molecules discussed above. The only identified molecule in Neovastat is the kappa light chain (which had the ability to stimulate tPA activity; see Ref. 201) , which cannot be considered cartilage specific.
Attempts to identify individual shark cartilage components that demonstrate antiangiogenic properties showed sequence similarity to alpha parvalbumin family (SCP1 protein) (Ref. 202) There is no simple explanation for the overall disappointment with these molecules. In the case of Neovastat, lack of PK/PC data was considered a hindrance to analyse its failure. But PK/PC values are available for TSP1 and endostatin, but have not helped in alleviating their failures. Peptide mimetics of TSP2 have not been reported and considering the lack of significant benefit from TSP1, antiangiogenic properties of TSP2 might need further evaluation. The mechanisms of inhibitory processes for most of these molecules are only marginally understood. Understanding the complete antiangiogenic mechanism might better prepare us for clinical trials. This can be exemplified for endostatin where a lack of understanding of the ZBP domain in the Nterminus led to the use of P. pastoris expressed, N-terminally truncated, recombinant human endostatin in clinical trials, which did not demonstrate any therapeutic efficacy. The genetic heterogeneity of the human population could also be a hindrance to translating the success from the preclinical, syngeneic mouse models. Formulating a new strategy or criteria for testing antiangiogenic molecules might be necessary before any further investments in clinical trials. expert reviews The criteria of what is a better biomarker of a successful clinical trial might also need to be revisited. Antiangiogenesis prevents blood vessel formation that shrinks tumours, rather than by being cytotoxic; this is a slow process that might need time for characterisation and recognition of the clinical end point. Antiangiogenesis remains an attractive therapeutic application, but it would appear that its sources need to be scrupulously and completely understood to translate them into beneficial clinical applications. The article is in Chinese and therefore we were unable to review it. It is the only published Phase III clinical trial for endostatin in humans, and readers may be interested in the abstract that is available in English in PubMed (PMID: 21108883), which suggests a beneficial response in NSCLC patients treated with endostatin when combined with chemotherapy. This article describes an endostatin network that involves physical interaction with other proteins including TSP1 and SPARC identified by surface plasmon resonance studies, indicating the extremely complicated mode of endostatin behaviour.
These three reviews discuss the impediments to treating tumours by chemotherapy and the importance of the antiangiogenic approach to normalise blood vessels to allow for better drug uptake. The following three reviews of SPARC are recommended as they summarise the early work done on SPARC, its numerous biological functions, crystal structure and its role primarily in ECM assembly: Features associated with this article (continued) 
